CPRX - カタリスト・ファ―マシュ―ティカルズ (Catalyst Pharmaceuticals Inc.) カタリスト・ファ―マシュ―ティカルズ

 CPRXのチャート


 CPRXの企業情報

symbol CPRx
会社名 Catalyst Pharmaceuticals Inc (カタリスト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カタリスト・ファーマシューティカル(Catalyst Pharmaceuticals Inc. )(旧名:Catalyst Pharmaceutical Partners Inc.)は、開発段階のバイオ医薬品会社である。同社は、希少な衰弱性疾患を患うの人々のための治療法の開発及び商品化に注力する。同社には、「Firdapse」、「CPP-109」及び「CPP-115」の3品目の開発中の薬剤がある。「Firdapse」は、ランバート摂食筋萎縮症候群(LEMS)及び先天性筋無力症候群(CMS)の治療に適応され、amifampridineのリン酸塩から構成される。「Firdapse」の第Ⅲ相試験は完了した。「CPP-109」は、γ-アミノ酪酸(GABA)アミノトランスフェラーゼ阻害剤であり、トゥレット症候群の治療に適応される。「CPP-115」は、GABAアミノトランスフェラーゼ阻害剤であり、複雑な部分発作、トゥレット症候群及びてんかん発作などの神経学的適応症の治療に適応される。   カタリスト・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。神経筋と神経疾患をタ―ゲットとして処方薬の開発と商業化に従事。筋力低下を特徴とする自己免疫疾患であるランバ―ト・イ―トン症候群の治療薬Firdapse、乳児けいれんの治療薬CPP-115、トゥレット症候群治療CPP-109の開発を行う。本社はフロリダ州。   Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and other neurological and neuromuscular disorders. Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ('FDA'), and Firdapse is now commercially available in the United States. Further, Canada's national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.
本社所在地 355 Alhambra Circle Suite 1250 Coral Gables FL 33134 USA
代表者氏名 Patrick James McEnany パトリック・ジェームス・マッケナニー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 305-529-2522
設立年月日 38899
市場名 NASDAQ Small Cap
ipoyear 2006年
従業員数 21人
url www.catalystpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cprx
adr_tso
EBITDA EBITDA(百万ドル) -22.05182
終値(lastsale) 3.39
時価総額(marketcap) 347811484.62
時価総額 時価総額(百万ドル) 339.60350
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 271.19460
当期純利益 当期純利益(百万ドル) -21.23038
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Catalyst Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $11.7M. Higher net loss reflects reasear increase of 32% to $6.4M (expense) General and administrative - Balancing increase of 57% to $4.1M (expense) Stock-based Compensation in SGA increase of 23% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.11.

 CPRXのテクニカル分析


 CPRXのニュース

   Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer  2021/07/06 12:03:00 Intrado Digital Media
CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Dr. Preethi Sundaram as Chief Product Development Officer. This position will report to the Chief Executive Officer.
   Catalyst Pharmaceuticals Appoints Pharmaceutical Executive  2021/07/03 10:47:00 Intrado Digital Media
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors GlobeNewswire
   Catalyst Pharmaceuticals Announces Exclusive License and  2021/07/02 02:16:30 Intrado Digital Media
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization GlobeNewswire
   Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors - Stocks News Feed  2021/06/29 12:03:00 Stocks News Feed
CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Molly Harper to the Companys Board of Directors. On behalf of the Board of Directors, Read More »Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
   Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors  2021/06/29 12:03:00 Intrado Digital Media
CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Molly Harper to the Companys Board of Directors.
   Catalyst Pharmaceuticals, Inc.''s and KYE Pharmaceuticals'' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®  2021/06/03 19:09:00 Benzinga
MISSISSAUGA, ON , June 3, 2021 /CNW/ - Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX ) , a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases , and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada''s approval of Medunik''s New Drug Submission (NDS) for Ruzurgi ® . The lawsuit sought judicial review of Health Canada''s decision to approve the NDS for Ruzurgi ® (Jacobus Pharmaceutical''s amifampridine product distributed in Canada by Medunik) and issue a Notice of Compliance ("NOC") on August 10, 2020 , as unreasonable due to Ruzurgi ® ''s product monograph and NDS explicitly referencing data included in Firdapse ® ''s NDS, approved
   Catalyst Pharmaceuticals, Inc.s and KYE Pharmaceuticals Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi  2021/06/03 17:20:00 Wallstreet:Online
- Without an NOC, Ruzurgi is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapses Data Protection CORAL GABLES, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on
   Catalyst: An A+ Quant Call, On The Edge  2021/06/03 07:26:48 Seeking Alpha
   Catalyst Pharmaceuticals, Inc.''s and KYE Pharmaceuticals'' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi  2021/06/03 00:00:00 BioSpace
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada''s approval of Medunik''s New Drug Submission (NDS) for Ruzurgi®.
   Catalyst Pharmaceuticals, Inc.s and KYE Pharmaceuticals Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®  2021/06/03 00:00:00 BioSpace
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canadas approval of Meduniks New Drug Submission (NDS) for Ruzurgi®.
   Catalyst Pharma 4Q Revenue, Earnings Outperform Estimates  2021/03/16 14:38:42 Smarter Analyst
Catalyst Pharmaceuticals delivered a better-than-expected 4Q performance, driven by higher sales for Firdapse, which is used to treat Lambert-Eaton myasthenic syndrome (LEMS) patients. … The post Catalyst Pharma 4Q Revenue, Earnings Outperform Estimates appeared first on Smarter Analyst .
   Catalyst Pharmaceuticals Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/15 18:23:00 Stock Market Daily
Catalyst Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Catalyst Pharma, TherapeuticsMD May Be Next WallStreetBets Targets  2021/01/29 12:37:43 24/7 Wall street
   Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold  2020/11/03 15:18:45 InvestorPlace
Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.
   Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020  2020/11/02 13:03:00 GlobeNewswire
CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カタリスト・ファ―マシュ―ティカルズ CPRX Catalyst Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)